Apremilast: a review in psoriasis and psoriatic arthritis
GM Keating - Drugs, 2017 - Springer
Apremilast (Otezla®) is an orally administered, small molecule inhibitor of
phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate …
phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate …
Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
GM Keating - Drugs, 2017 - europepmc.org
Apremilast (Otezla®) is an orally administered, small molecule inhibitor of
phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate …
phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate …
[引用][C] Apremilast: A Review in Psoriasis and Psoriatic Arthritis
GM Keating - Drugs, 2017 - cir.nii.ac.jp
Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
G Keating - Drugs, 2017 - search.ebscohost.com
Apremilast (Otezla) is an orally administered, small molecule inhibitor of phosphodiesterase
4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate to severe plaque …
4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate to severe plaque …
Apremilast: A Review in Psoriasis and Psoriatic Arthritis
GM Keating - Drugs, 2017 - infona.pl
Apremilast (Otezla®) is an orally administered, small molecule inhibitor of
phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate …
phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate …
Apremilast: A Review in Psoriasis and Psoriatic Arthritis
GM Keating - Drugs, 2017 - search.proquest.com
Apremilast (Otezla®) is an orally administered, small molecule inhibitor of
phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate …
phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate …
Apremilast: A Review in Psoriasis and Psoriatic Arthritis
GM Keating - Drugs, 2017 - pubmed.ncbi.nlm.nih.gov
Apremilast (Otezla®) is an orally administered, small molecule inhibitor of
phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate …
phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate …